BACKGROUND: Although 2 doses of influenza vaccine are recommended for children aged <9 years who have not been previously vaccinated, children may receive only 1 dose because of suboptimal adherence to national influenza vaccination recommendations. OBJECTIVE: This study evaluated the efficacy and tolerability of a single dose of the live attenuated influenza vaccine (LAIV) in previously unvaccinated children aged > or = 2 years, the population for which LAIV is approved. METHODS: This study was a post hoc subgroup analysis of previously published studies. Three randomized, double-blind, placebo-controlled clinical trials have evaluated the efficacy of a single dose of LAIV in previously unvaccinated young children. Single-dose efficacy, as a prespecified outcome, was evaluated in the subgroup of children aged 2 to 6 years. Reactogenicity and adverse events through 10 days after vaccination were reported after 1 and 2 doses. RESULTS: Across all studies combined, the mean (SD) ages of the children within the subgroups analyzed were 35.8 (12.1) months for LAIV recipients and 34.5 (11.3) months for placebo recipients. The groups were balanced by sex, with 51% and 50% boys in the LAIV and placebo groups, respectively. The LAIV and placebo groups were also balanced with regard to the countries of origin, as follows: United States (35% LAIV, 31% placebo), Southeast Asia (35% LAIV, 44% placebo), South America (19% LAIV, 15% placebo), and South Africa (11% LAIV, 11% placebo). In a post hoc subgroup analysis of children aged 2 to 6 years from these 3 studies, the efficacy of a single dose of LAIV compared with placebo was 71.5% (95% CI, 52.9% to 83.4%), 87.3% (95% CI, 59.2% to 96.1%), and 59.9% (95% CI, 31.1% to 77.4%). Two of the studies compared the efficacy of 1 and 2 doses of vaccine in the same season. The 1-dose efficacy of LAIV was 87% to 92% of the 2-dose efficacy. Upon revaccination in year 2 with a single dose, year-2 efficacy was not significantly different for children who received either 1 or 2 doses in year 1 (1 dose in year 1, efficacy 64.1% [95% CI, 13.1% to 85.7%]; 2 doses in year 1, efficacy 55.4% [95% CI, -23.6% to 85.9%]; P = NS). All reactogenicity events associated with the first dose of LAIV were decreased after the second dose, with the exception of cough. CONCLUSIONS: A single dose of LAIV provided significant but not optimal protection against influenza in previously unvaccinated children. This finding may be of particular importance for children who are at risk of being partially immunized.
RCT Entities:
BACKGROUND: Although 2 doses of influenza vaccine are recommended for children aged <9 years who have not been previously vaccinated, children may receive only 1 dose because of suboptimal adherence to national influenza vaccination recommendations. OBJECTIVE: This study evaluated the efficacy and tolerability of a single dose of the live attenuated influenza vaccine (LAIV) in previously unvaccinated children aged > or = 2 years, the population for which LAIV is approved. METHODS: This study was a post hoc subgroup analysis of previously published studies. Three randomized, double-blind, placebo-controlled clinical trials have evaluated the efficacy of a single dose of LAIV in previously unvaccinated young children. Single-dose efficacy, as a prespecified outcome, was evaluated in the subgroup of children aged 2 to 6 years. Reactogenicity and adverse events through 10 days after vaccination were reported after 1 and 2 doses. RESULTS: Across all studies combined, the mean (SD) ages of the children within the subgroups analyzed were 35.8 (12.1) months for LAIV recipients and 34.5 (11.3) months for placebo recipients. The groups were balanced by sex, with 51% and 50% boys in the LAIV and placebo groups, respectively. The LAIV and placebo groups were also balanced with regard to the countries of origin, as follows: United States (35% LAIV, 31% placebo), Southeast Asia (35% LAIV, 44% placebo), South America (19% LAIV, 15% placebo), and South Africa (11% LAIV, 11% placebo). In a post hoc subgroup analysis of children aged 2 to 6 years from these 3 studies, the efficacy of a single dose of LAIV compared with placebo was 71.5% (95% CI, 52.9% to 83.4%), 87.3% (95% CI, 59.2% to 96.1%), and 59.9% (95% CI, 31.1% to 77.4%). Two of the studies compared the efficacy of 1 and 2 doses of vaccine in the same season. The 1-dose efficacy of LAIV was 87% to 92% of the 2-dose efficacy. Upon revaccination in year 2 with a single dose, year-2 efficacy was not significantly different for children who received either 1 or 2 doses in year 1 (1 dose in year 1, efficacy 64.1% [95% CI, 13.1% to 85.7%]; 2 doses in year 1, efficacy 55.4% [95% CI, -23.6% to 85.9%]; P = NS). All reactogenicity events associated with the first dose of LAIV were decreased after the second dose, with the exception of cough. CONCLUSIONS: A single dose of LAIV provided significant but not optimal protection against influenza in previously unvaccinated children. This finding may be of particular importance for children who are at risk of being partially immunized.
Authors: Laetitia Gerlier; Mark Lamotte; Sofia Dos Santos Mendes; Oliver Damm; Markus Schwehm; Martin Eichner Journal: Paediatr Drugs Date: 2016-08 Impact factor: 3.022
Authors: Sara Boccalini; Elena Pariani; Giovanna Elisa Calabrò; Chiara DE Waure; Donatella Panatto; Daniela Amicizia; Piero Luigi Lai; Caterina Rizzo; Emanuele Amodio; Francesco Vitale; Alessandra Casuccio; Maria Luisa DI Pietro; Cristina Galli; Laura Bubba; Laura Pellegrinelli; Leonardo Villani; Floriana D'Ambrosio; Marta Caminiti; Elisa Lorenzini; Paola Fioretti; Rosanna Tindara Micale; Davide Frumento; Elisa Cantova; Flavio Parente; Giacomo Trento; Sara Sottile; Andrea Pugliese; Massimiliano Alberto Biamonte; Duccio Giorgetti; Marco Menicacci; Antonio D'Anna; Claudia Ammoscato; Emanuele LA Gatta; Angela Bechini; Paolo Bonanni Journal: J Prev Med Hyg Date: 2021-09-10
Authors: Nicole A Karras; Matthew Weeres; Wendy Sessions; Xiyan Xu; Todd Defor; Jo-Anne H Young; Heather Stefanski; Claudio Brunstein; Sarah Cooley; Jeffrey S Miller; Bruce R Blazar; John E Wagner; Michael R Verneris Journal: Biol Blood Marrow Transplant Date: 2012-08-29 Impact factor: 5.742
Authors: Maria del Pilar Martin; William C Weldon; Vladimir G Zarnitsyn; Dimitrios G Koutsonanos; Hamed Akbari; Ioanna Skountzou; Joshy Jacob; Mark R Prausnitz; Richard W Compans Journal: mBio Date: 2012-03-06 Impact factor: 7.867
Authors: Oliver Damm; Martin Eichner; Markus Andreas Rose; Markus Knuf; Peter Wutzler; Johannes Günter Liese; Hagen Krüger; Wolfgang Greiner Journal: Eur J Health Econ Date: 2014-05-25
Authors: John C Victor; Kristen D C Lewis; Aldiouma Diallo; Mbayame N Niang; Bou Diarra; Ndongo Dia; Justin R Ortiz; Marc-Alain Widdowson; Jodi Feser; Rebecca Hoagland; Shannon L Emery; Kathryn E Lafond; Kathleen M Neuzil Journal: Lancet Glob Health Date: 2016-10-13 Impact factor: 26.763